



ENLIGHT:

Education & Training

Manjit Dosanjh
CERN&ENLIGHT

www.cern.ch/enlight

ENLIGHT was launched 15 years ago

- ENLIGHT was launched in February 2002 at CERN
- Idea germinated in 2001 in MedAustron meeting where PIMMS was presented




DG: Luciano Maiani

Organisers: Manjit Dosanjh & Hans Hoffmann


ENLIGHT was established to collaborate

- Create common multidisciplinary platform
- Cancer treatment
- Identify challenges
- Share knowledge
- Share best practices
- Harmonise data
- Provide training, education
- Innovate to improve
- Lobbying for funding
- Raising awareness




Leveraging Physics collaboration philosophy into a multidisciplinary medical environment

ENLIGHT is an open collaborative network



PARTNER – a success story

- Particle Training Network for European Hadrontherapy
- 10 academic institutes, research centres, 2 leading companies
- 29 young researchers




Outcome :

- Now working around the World
- Open access PARTNER-JRR


Particle Training Network for European Radiotherapy

Researchers on the move



Particle Training Network for European Radiotherapy

Now working in...




ENTERVISION

- Training Network for medical imaging
- 10 academic institutes, research centres, IBA leader PT
- 12 Early Stage Researchers
- 3 Experienced Researchers

European training network in digital medical imaging for radiotherapy

Researchers on the move



Outcome :

- 11 PhDs
- Over 30 posters, 50 oral presentations and 35 publications
- Patent for prompt gamma camera
- Frontiers in Oncology: Special Issue with 11 articles written by Entervision researchers in an open-access journal

<http://journal.frontiersin.org/researchtopic/3520/charged-particles-in-oncology>

15 THINGS in 15 YEARS!

700 members from all continents

25+ countries

15 annual meetings

50 training courses

5 EU projects

45 Marie Curie fellowships

2 dedicated issues in open-access journals

200+ journal publications

500+ posters and presentations

4 Physics for Health conferences

10+ video animations

8 ENLIGHT Highlights

2 European Researchers' Nights

50 outreach articles/news

One global multidisciplinary network

Particle therapy centres in Europe - 2002




Particle Therapy Centres in Europe


2016

©ENLIGHT, 2016


- In operation:
- Proton
 - Dual Ion
- Under construction:
- ▲ Proton
 - ▲ Dual Ion
- Being planned:
- ◆ Proton
 - ◆ Dual Ion



Particle therapy facilities in operation, under construction & planning



Particle Therapy Facilities in Operation & Construction/ Planning Phase in Europe



ENLIGHT: meet urgent need for education & training

ENLIGHT Project submitted to **CERN & Society Foundation** for training and education in 2016 and just approved:

Project comprises of three types of training:

1. Introductory Multidisciplinary Training
2. Advanced Training including hands-on
3. Individual longer-term internship

Knowledge Transfer 2014



Carbon-ion gantry at the Heidelberg Ion-Beam Therapy Centre, Germany

From physics to medicine

State-of-the-art techniques borrowed from particle accelerators, detectors and physics computing are increasingly used in the medical field for both diagnosis and treatment of a variety of diseases.

CERN's core



BioLEIR

A WORLD-LEADING BIOMEDICAL RESEARCH FACILITY FOR IMPROVED CANCER THERAPY

Cancer is the second cause of death in Europe, where more than 3.2 million people are diagnosed with the disease every year. A study published in The Lancet Oncology in 2012 shows that, by 2030, the global incidence of cancer is expected to increase by more than 75% in developed countries and by more than 90% in developing countries.



An open-access biomedical research facility

BioLEIR will enable more rapid progress in the development of hadron therapy, one of the most promising and innovative weapons in the fight against cancer. Hadron therapy, an advanced radiotherapy technique, treats tumours with protons or other ions, which can be tuned to deliver their dose precisely when the tumour target, effectively sparing the surrounding healthy tissues.

BioLEIR will provide beams of different ions at various energies, thus allowing medical and radiobiological collaborators to fully investigate their biological impact on tumour cells and biological material, and then to optimise hadron therapy for different cancer types. BioLEIR will also allow physicists to test innovative particle detectors and to perform accurate nuclear fragmentation studies, in order to improve medical imaging techniques and treatment planning.

Why at CERN?

The need for an open-access biomedical research facility was first raised by the scientific community at the 2010 Physics for Medicine workshop, where CERN was asked to take the lead on this project. In 2012, a brainstorming meeting evaluated the existing CERN Low Energy Ion Ring (LEIR) as a potential site for BioLEIR.

CERN makes the technologies developed for its research available to society, most notably the World Wide Web, invented at CERN and generously put into the public domain so that it is freely available to all.

CERN has gathered considerable expertise in hadron therapy through the coordination of several projects related in the field.


How?

BioLEIR will rely on the LEIR accelerator, which is used typically for a few months each year for pre-accelerating heavy ions for the Large Hadron Collider.

Adapting the existing infrastructure for biomedical use is outside the scope of CERN's core activities, and will take up to 3 years to complete. Financial support will be needed to cover the modifications of the LEIR machine that are specific to the biomedical requirements, and for the actual biomedical research activities.

Manpower costs will be covered for the most part by CERN. CERN will also provide administrative support for visiting scientists, but needs additional funding annually to hire a medical physicist who would provide full-time support to the biomedical experiments, as well as to cover young scientists' residency and travel allowances.

The running costs for both LEIR and BioLEIR are covered by the overall running costs of the CERN accelerator complex. The estimate of the modification costs not covered by CERN is around 10% of the total capital invested in this research.



THE FCC STUDY

Towards a future circular collider p16

FERMILAB

MINERVA: a new step for neutrino cross-sections

CERN

Collaboration and growth in the 1980s p50




EUROPEAN HADRON THERAPY COMMUNITY TOUCHES BASE

The European hadron therapy community gathered in Stockholm from 3 to 5 June 2013 for the annual ENLIGHT workshops. Three of the four EC-funded projects under the umbrella of ENLIGHT (see box) were discussed in the prestigious Nobel Forum at the Karolinska Institutet.



On its second birthday, the PARTNER Initial Training Network was especially under the spotlight, as the European Commission conducted a formal project review bringing together the institutes, companies and young researchers involved. The 21 PARTNER researchers experienced the thrill of presenting their work in this privileged setting. During the coffee breaks, they joked about this being their only chance in life to speak to brilliant young minds will meet Project Officer Gianluca



Pan European Networks

Science & Technology

PEN MET WITH PROFESSOR MANJIT DOSANJH, CERN'S LIFE SCIENCES ADVISOR, AT ESOF 2014, WHERE SHE OUTLINED HOW THE LIFE SCIENCES STAND TO BENEFIT FROM DEVELOPMENTS MADE BY THE PHYSICS COMMUNITY

Transferring knowledge

Over recent decades, many important diagnostic and therapeutic techniques have been built on either basic physics principles or the tools developed to conduct physics research. A notable example is the technique of positron emission tomography (PET), a technology which emerged in the medical community but owes much to research in particle physics.

As such, CERN – the European Organization for Nuclear Research – has a knowledge transfer group, within which efforts are made to transfer the technologies developed and utilised in the physics community to areas outside basic research, including Life Sciences and, in particular, medicine.

At the EuroScience Forum (ESOF) 2014 event in Copenhagen, Pan European Networks met with Prof Manjit Dosanjh, CERN's Life Sciences advisor and deputy group leader of the Knowledge Transfer Group, where she outlined how Life Sciences and cancer treatments, in particular stand to benefit from developments made by the physics community, and the hurdles she had to overcome in her 14 years at the organisation.


Doctors, of course, have to treat patients, and therefore applications need to be developed fast. Physicists, on the other hand, plan their experiments and their infrastructures for long periods of time.

Which could be relevant for society at large, examples include the World Wide Web and touchscreen technology.

While the Life Sciences were not a part of CERN's primary mandate, member states had to look at the various technologies from here, we began to develop, and how we could help our member states. It is clear that since health is a key societal issue and affects all of us, it should be a high priority for the Knowledge Transfer Group. My role is, fundamentally, to build bridges between the physics community and the medical community outside CERN and act somewhat as a catalyst.

Secondly, knowing that this exploration of the Life Sciences would not be handed through CERN, I must...

What has been your main role in CERN's Life Sciences



- Imaging Data
- Dose Prescription
- Simulation Data
- Run Simulation



Participants in the training



ENLIGHT 2018 will be held in London
25-27 June

Looking forward to seeing you there
www.cern.ch/enlight

